212 articles - From Friday May 16 2025 to Friday May 23 2025
Guidelines and related publications, position statements, white papers, technical reviews, consensus statements, etc…
| Clin Gastroenterol Hepatol |
|---|
Clinical Practice Updates: AGA Clinical Practice Update on GI Manifestations and Autonomic or Immune Dysfunction in Hypermobile Ehlers-Danlos Syndrome: Expert Review. Dietary interventions should be delivered with appropriate nutritional counseling or guidance to avoid the pitfalls of restrictive eating. BEST PRACTICE ADVICE 16: Management of chronic GI symptoms in patients with hEDS/HSDs who do not exhibit symptoms consistent with POTS or MCAS should align with existing approaches to management of DGBI and GI motility disorders in the general population, including integrated multidisciplinary care involving multiple specialties, where appropriate (eg, cardiology, rheumatology, dietician, psychology). |
meta-analyses and systematic reviews
| Am J Gastroenterol |
|---|
EFFICACY OF REBAMIPIDE IN THE PREVENTION OF NSAID-INDUCED GASTROINTESTINAL MUCOSAL BREAKS: A SYSTEMATIC REVIEW AND META-ANALYSIS. Rebamipide is effective in preventing NSAID-induced gastrointestinal mucosal breaks. Rebamipide may also be as good as the standard PPIs in preventing NSAID-induced gastrointestinal mucosal breaks, and hence may be an alternative especially in those with contraindications to long term PPI use. |
Immune-related Adverse Events are Associated with Improved Outcomes after Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. The development of irAEs is associated with favorable clinical outcomes in HCC, including improved PFS and higher ORR. OS benefit was noted in patients with mild irAEs but not those with severe irAEs. |
Yoga for Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. With uncertain evidence, yoga did not reduce the GI severity of symptoms, anxiety, depression, or improve QoL in IBS patients. In light of the considerable methodological heterogeneity and the high risk of bias within the included RCTs, Yoga cannot be recommended as a treatment for IBS before conducting further large-scale RCTs to fill the current evidence gaps. |
| Clin Gastroenterol Hepatol |
DIAGNOSIS AND MANAGEMENT OF UPPER GASTROINTESTINAL INVOLVEMENT IN ADULT PATIENTS WITH CROHN'S DISEASE: A SYSTEMATIC REVIEW. We highlight the need for the development of standardized guidance in both diagnosing and managing UGICD. This work serves as preparation for an international consensus on the management of UGICD. |
GLOBAL EPIDEMIOLOGY OF PRIMARY BILIARY CHOLANGITIS: AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS. The rising prevalence of PBC represents a growing healthcare burden in Western Pacific region. The positive association between latitude and PBC prevalence require further studies. |
Immunogenicity and efficacy of subcutaneous infliximab monotherapy versus combination therapy in IBD: a systematic review and meta-analysis. SC IFX monotherapy is associated with higher immunogenicity rates compared to combination therapy, particularly in new IFX starters. Although clinical response was comparable, a trend favouring combination therapy warrants further investigation. |
| Endosc Int Open |
Biliary stent insertion after stone clearance in patients awaiting cholecystectomy: Systematic review and meta-analysis. This meta-analysis showed no benefit for stent insertion after bile duct clearance in patients scheduled for delayed cholecystectomy. Further randomized controlled trials with bigger cohorts are needed to assess any benefit for this procedure, which in the meantime, cannot be recommended. |
RCT, clinical trials, retrospective studies, etc…
| Aliment Pharmacol Ther |
|---|
Anthropometric Measures and Mortality Risk in Individuals With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Population-Based Cohort Study. WC and WC-related indices are better parameters in prognosticating MASLD than BMI. The BMI-related 'obesity paradox' may be a misnomer resulting from the use of an incorrect metric. WC should be measured more routinely among individuals with MASLD. |
Clearance of Hepatitis C Viremia During Direct-Acting Antiviral Therapy Leads to Rapid Changes in Lipid and Lipoprotein Metabolism. Serum lipids and lipoproteins rapidly increase with inhibition of viral replication during DAA therapy, an effect that may be mediated by genes affecting hepatic de novo lipogenesis. Based on lipid changes, HCV eradication may increase CVD risk, but this needs to be investigated prospectively. |
Effectiveness and Safety of a Second JAK Inhibitor in Ulcerative Colitis: The J2J Multicentre Study. No cases of death, cancer, or major acute cardiovascular events were reported. A second-line of JAKi provided clinical remission in about half of patients after induction, and was well tolerated. |
Long-Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver-Related Events in Nucleos(t)ide Analogue-Treated Chronic Hepatitis B Patients in China. On-treatment ALT levels were significantly correlated with the prognosis of CHB. ALT ≤ 23 U/L for men and ≤ 16 U/L for women were identified as the optimal thresholds during NA treatment, suggesting that CHB patients should strive for a lower ALT level beyond the traditional normal range. |
Real-World Effectiveness of Budesonide Orodispersible Tablets for Eosinophilic Oesophagitis: The Importance of Patience and Education. Adverse events were reported by 16% of patients and 17% were noted to have incorrect technique of administration. BOT was demonstrated to have lower rates of clinicohistological remission in real-world practice than reported in clinical trials, largely due to incorrect technique and cessation due to adverse events. |
Some Risks of Gastrointestinal Adverse Events Associated With Glucagon-Like PEPTIDE-1 Receptor Agonists Are Likely Explained by BMI. Not matching for BMI suggested an elevated pancreatitis risk (aHR 1.75; 95% CI 1.13-2.70). Semaglutide conferred superior weight loss but increased biliary risk. |
Volatomics for Diagnosis and Risk Stratification of MASLD: A Proof-Of-Concept Study. eNose can discriminate patients with MASLD from healthy volunteers and, using unbiased clustering analysis, identify patients with a significantly worse prognosis. These results warrant prospective validation in independent MASLD populations. |
| Am J Gastroenterol |
13C-Spirulina Gastric Emptying Breath Test Normative Values in Healthy Children- A Multicenter Study with Comparison to Symptomatic Children. This study demonstrates sex and pubertal differences in gastric emptying in children and provides the first reference values for female children. |
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Metopimazine Mesylate (NG101) in Participants with Gastroparesis. While NG101 did not meet statistical significance in its primary endpoint for reducing nausea severity, it demonstrated a favorable safety profile and significant improvement in some secondary endpoints. Further study is needed to determine if NG101 is an effective treatment for patients with idiopathic gastroparesis. |
Artificial Intelligence in Gastroenterology Education: DeepSeek Passes the Gastroenterology Board Examination and Outperforms Legacy ChatGPT Models. DeepSeek exhibited passing performance on the gastroenterology board examination, but gaps in niche topics and image exclusion limit utility. It may supplement education if validated by specialists. |
CLINICAL CHARACTERISTICS AND PATHOPHYSIOLOGY OF FECAL INCONTINENCE MIXED WITH CONSTIPATION (FI-MC): AN UNDERRECOGNIZED PROBLEM. FI patients can be categorized into two phenotypes as FI alone and FI-MC. Each group demonstrates distinct clinical characteristics and pathophysiology. Recognizing each phenotype may improve management of FI patients. |
Comparing precutting endoscopic mucosal resection using snare-tip and ESD knife for large nonpedunculated colorectal polyps: a randomized controlled trial. EMR-P using a snare-tip was non-inferior to EMR-P using a ESD knife for large non-pedunculated colorectal polyps. EMR-P using a snare-tip is considered as effective and safe as an ESD knife. |
Gender-Affirming Hormone Therapy and Risk of IBD Flare in Transgender and Gender Diverse Adults. While there was no overall increased risk of flare in the year after GAHT start, those with active IBD prior to hormone start and those who received testosterone were more likely to experience an IBD flare. |
Glucagon-Like Peptide-1 Receptor Agonists Use Does Not Increase the Risk for Acute Pancreatitis and Is Associated with Lower Complications in Patients with Type 2 Diabetes Who Develop Acute Pancreatitis: A Multi-Center Analysis. GLP-1 RAs use does not increase AP risk, is associated with lower complications in those who developed AP and linked with lower all-cause mortality in T2DM patients. Prospective studies are needed to determine the mechanisms behind these findings. |
Hereditary Alpha-Tryptasemia is Associated with Ongoing Symptoms in Individuals with Celiac Disease Despite Following a Gluten-Free Diet. The prevalence of HαT in CeD is similar to the general population, however, al participants with CeD and HαT had ongoing GI symptoms. Evaluation for HαT should be considered in the management of CeD patients with persisting symptoms. |
Overlap of esophageal disorders of gut-brain interactions (E-DGBIs) and GERD is highly prevalent in patients with refractory reflux symptoms. E-DGBIs are highly prevalent in patients with proven GERD and refractory reflux symptoms. Studies with outcome data are needed to determine whether patients with overlapping E-DGBIs and GERD should be identified with pH-impedance monitoring on PPI therapy before an interventional treatment option is considered. |
Sarcopenia is an Independent Risk Factor for the Decline in Anal Sphincter Function and Increased Levator Laxity in Women. Sarcopenia significantly impacts anal sphincter function and pelvic floor dynamics in women with evacuation disorders, serving as a risk factor for anal hypotension/hypocontractility and levator laxity. These findings highlight the need for integrated approaches in managing pelvic floor disorders, taking into account the role of muscle mass and strength in treatment strategies. |
The Role of Patient-Reported Outcomes in Cirrhosis. These reports are termed patient-reported outcomes (PROs) and defined as any report of the status of a patient's health condition that comes directly from the patient, without interpretation of the patient's response by a clinician or anyone else. This review aims to provide an overview of what are PROs, types of validated instruments to measure PROs in cirrhosis and the benefits of using PROs in the care of patients with cirrhosis. |
| Clin Gastroenterol Hepatol |
A New International Scheme for the Classification and Management of Clinical Outcomes Post-Gastric Peroral Endoscopic Myotomy. Our study highlights the importance of post-G-POEM GES assessments for characterizing clinical responses. Type 1 responders are more likely to benefit from subsequent pylorus-directed re-treatments, particularly repeat G-POEM interventions. |
A pilot randomized control trial to assess the adjunctive effect of diet on response to advanced therapies in patients with UC. The LC-PB diet did not improve clinical response to medications. However, it led to clinical improvement, steroid tapering, and reduced SAA. As results were limited by sample size, larger studies are needed. |
Ambulatory Acute Kidney Injury in Patients with Cirrhosis is Common and Burdensome. A-AKI is common in cirrhosis, associated with high 90-day mortality, and significantly under-recognized. Targeted interventions for early diagnosis and treatment could improve outcomes in high-risk patients. |
Association of metabolic comorbidities with fibrosis severity and fibrosis regression in patients with chronic hepatitis B. Presence of metabolic comorbidities in untreated CHB patients is associated with more severe liver fibrosis and, after initiation of AVT, with less fibrosis regression and a higher risk of fibrosis progression. |
Insulin-like Growth Factor-1 reflects liver disease stage and improves prediction of liver-related mortality. The study highlights the usefulness of IGF-1 as a reliable predictor of LRD and identifies a novel, population-based screening tool outperforming the currently used scores. |
Long-term mortality after cholecystectomy in a nationwide cohort of Swedish individuals between 1969 and 2016. In a nationwide, Swedish cohort, we observed that cholecystectomy at younger age was associated with higher long-term mortality, potentially influenced by higher alcohol use and smoking. The inverse association among individuals >50 may reflect better underlying health of individuals selected for cholecystectomy. |
Outcomes of Allogeneic Hematopoietic Stem Cell Transplant in Monogenic Inflammatory Bowel Disease. HSCT resulted in IBD medication-free remission and reduction in disease-associated complications. This highlights the strength of genetic evaluation in patients with VEO-IBD or refractory IBD and consideration of HSCT, which can be curative and lifesaving in patients with monogenic defects involving immune dysfunction. |
PErsistence and safety of subcutaneous infliximab 1 year after switch from intravenous route in IBD patients in REMission. In this large multicenter prospective cohort, persistence at one year of SC-IFX was more than 95% of IBD patients switched in remission from IV-IFX, confirming excellent effectiveness and tolerance of SC-IFX. |
Rethinking post-colonoscopy colorectal cancer risk: endoscopist performance versus presence of high-risk polyps. An individual's PCCRC-risk in the initial years is primarily influenced by endoscopist performance, rather than the presence of high-risk polyps. To reduce PCCRCs, besides ensuring appropriate surveillance intervals, it is crucial to monitor and audit endoscopist quality indicators. |
Simplifying Diagnosis of Bile Acid Diarrhea with Clinical and Biochemical Measurements on Blood and Single Stool Sample. New diagnostic cut-offs based on serum C4 and single stool TBAc and % PBA provide potential alternatives for diagnosing BAD. Further validation is warranted. |
Symptoms of Constipation: Relationship between questionnaires and diaries and Impact on Quality of Life. Bowel diaries characterize constipation symptoms in a refined manner; only 52% of participants satisfied constipation symptom criteria on both instruments. Somatic symptoms overshadow the contribution of bowel symptoms to QoL. |
pH IMPEDANCE MONITORING ON PROTON PUMP INHIBITOR THERAPY IMPACTS MANAGEMENT DECISIONS IN PROVEN GERD BUT NOT IN UNPROVEN GERD. A minority of symptomatic patients will have refractory GERD evidence on pH-impedance monitoring on-PPI; this strategy risks missing over half of the cohort with proven GERD if testing off-PPI is unavailable. Our findings support documenting GERD off-PPI first in PPI non-responders and restricting on-PPI pH-impedance monitoring to identify refractory GERD only in patients with proven GERD with persisting symptoms. NCT03202537. |
| Endosc Int Open |
Benefits of macroscopic on-site evaluation in endoscopic ultrasound-guided tissue acquisition for comprehensive genomic profiling. In tissue specimens obtained using endoscopic ultrasound-guided tissue acquisition, macroscopic visible core length can be associated with an appropriate sample for FoundationOne CDx. |
Comparative analysis of gastric emptying between patients undergoing EUS-guided gastroenterostomy and enteral stent placement: Pilot analysis. EUS-GE was associated with better gastric emptying compared with ES, suggesting a benefit that may translate into clinical benefit even in the short term. |
Contrast-enhanced vs. standard endoscopic ultrasound fine-needle aspiration for diagnosing malignant biliary tumors: Randomized controlled trial. Standard EUS-FNA and CH-EUS-FNA demonstrated comparable diagnostic accuracy in evaluation of extrahepatic bile duct tumors, but with better slightly efficiency and inaccuracy indices than standard EUS-FNA. |
Environmental footprint of a colonoscopy procedure: Life cycle assessment. Among the 13 colonoscopies studied, the environmental impact was mainly attributable to transportation of patients and staff, and disposables. Therefore, raising awareness about the impact of transportation by car, and reducing resource consumption, particularly of disposable products, should be prioritized. Implementing alternatives to colonoscopy, such as intestinal ultrasound, could reduce the environmental footprint of the healthcare system. |
Epithelium-preserving stricturotomy is effective for improving postoperative benign anastomotic stricture associated with colorectal surgery. Anastomotic stricture length ≥ 1 cm and non-epithelium preservatoin at ESt were independent risk factors for restricture after ESt in POBAS patients. These two factors may help predict risk of POBAS recurrence and provide reliable evidence for developing personalized treatment plans for patients. |
Impact of age and comorbidities on colorectal endoscopic submucosal dissection outcomes: Large multicenter study in a Western cohort. Colorectal ESD is feasible in elderly patients. Physicians should consider delirium a possible AE in patients older than age 80 years. These findings, which bridge the gap between Asian and Western clinical data, underscore the importance of tailored pre-procedure and post-procedure assessments in a global clinical context. |
Interobserver variability in lymph node evaluation with endoscopic ultrasonography in cholangiocarcinoma. Endosonographic assessment of LN morphology and characterization demonstrates considerable variability among endosonographers. Thus, there is a clear need for standardization in preoperative LN evaluation, including establishing consensus about when to perform tissue acquisition, based on objective criteria such as short-axis diameter. Further research is required to refine and optimize these guidelines. |
Journey to complete remission of dysplasia and intestinal metaplasia after ESD and EMR of Barrett's esophagus-related neoplasia. Despite larger lesion sizes and more cancers in patients undergoing ESD, the EET journey to achieving CRD and CRIM was comparable to that in patients receiving cEMR. Prospective studies are required to further study differences between these two treatment approaches. |
Medicolegal aspects of digestive endoscopy: Results of a Chilean national survey. Gastrointestinal endoscopists are frequently exposed to complaints and lawsuits. Key factors include procedure costs, AEs, sedation practices, years of experience, type of endoscopic procedure, and communication. Proactive strategies to address these factors could mitigate medico-legal risks and improve patient outcomes. |
Patient- and endoscopist-related risk factors and etiological categorization of post-colonoscopy colorectal cancer. Endoscopists detecting more adenomas had a substantially lower PCCRC incidence in their patients. Therefore, endoscopist performance is a crucial marker of PCCRC and may serve as a quality control measure for colonoscopy. |
Pilot evaluation of a novel, automated ergonomics assessment tool. ErgoGenius was successfully deployed to detect abnormal postures related to changes in bed position and quantify ERI risk. It performed at par with human appraisers. This tool shows promise in enhancing ergonomic practices among gastroenterologists and trainees, potentially leading to better health outcomes and reduced injury. |
Red dichromatic imaging enhances submucosal visibility during endoscopic submucosal dissection: Pilot study. RDI enhances visualization during ESD by improving visibility of the dissecting layer and increasing color differentiation compared with conventional WLI. These findings suggest that incorporating RDI into routine endoscopic practice could lead to more precise and efficient ESD procedures, ultimately improving patient outcomes. |
Retrospective case-control study of the impact of dialysis on bowel preparation scores. Safe and adequate BP is achievable in dialysis patients. Bowel preparation regimen rather than treatment with dialysis influences BP quality. Split-dose preparation remains the most important determinant of adequate BP for colonoscopy, irrespective of regimen. |
Use of artificial intelligence to measure colorectal polyp size without a reference object. Our study shows that colorectal polyp size measurement by AI model is practical and clinically useful, exhibiting low error rates and high precision. AI shows promise as an accurate tool for measurement without the need for a reference object during screening colonoscopy. |
| Endoscopy |
Prospective analysis of endoscopic impedance planimetry pyloric measurements and its association with clinical outcomes with gastric peroral endoscopic myotomy. Patients who responded to G-POEM had a lower baseline DI when compared to non-responders. Additional studies optimizing and standardizing FLIP protocols in patients undergoing G-POEM are needed. |
| Gastroenterology |
Associations of alcohol consumption and genetic predisposition to hepatic steatosis with liver-related events: results from large population-based cohort studies. Associations between alcohol intake and LREs vary across different drinking categories. Individuals with a higher genetic risk for SLD appear more susceptible to alcohol. |
Cost-effectiveness of regular surveillance versus endoscopy at need for patients with Barrett's esophagus: economic evaluation alongside the BOSS randomized controlled trial. BE surveillance every 2-3 years is unlikely to be a cost-effective strategy. Guidelines should take this into account when deciding surveillance intervals. |
Dietary fiber modulates the window of susceptibility to Clostridioides difficile infection. Consumption of a low-fiber diet after antibiotic use contributes to a prolonged susceptibility to CDI that corresponds to a perturbation in both microbiota and bile acid composition. These results suggest that in the context of antibiotic treatment, diet is a critical, modifiable risk factor for CDI susceptibility. |
Fidaxomicin reduces collagen expression in intestinal fibroblasts via platelet-derived growth factor receptor beta and glycogen synthase kinase-3 beta inhibition. Fidaxomicin inhibits intestinal fibrosis by reducing PDGFRβ phosphorylation and expression, GSK3β phosphorylation, and collagen expression in intestinal fibroblasts. |
Synergies between Clinicians, Academia and Industry in the Age of AI. Issues including data privacy, regulatory hurdles, and interdisciplinary communication must be addressed to foster effective partnerships. By embracing collaborative models, including public-private partnerships, clinical trials, and innovation hubs, stakeholders can work together to overcome barriers and promote responsible AI integration in gastroenterology. |
| Gastrointest Endosc |
The 2024 top 10 list of endoscopy topics in medical publishing: an annual review by the American Society for Gastrointestinal Endoscopy Editorial Board. The top 10 identified topics collectively represent advances in the following endoscopic areas: glucagon-like peptide-1 receptor agonists and endoscopy, advances in AI in endoscopy, ergonomics in endoscopy, peroral endoscopic myotomy, bariatric and metabolic endoscopy, endoscopic resection in the colon, gastric intestinal metaplasia and endoscopy, inflammatory bowel disease and endoscopy, GI bleeding risk stratification and endoscopic therapies, and therapeutic EUS. Board members were assigned a topic area and summarized relevant and important articles, thereby generating this overview of the "top 10" endoscopic advances of 2024. |
| Gut |
Activation of RAS/MEK/ERK signalling drives biliary differentiation in primary liver cancer. These findings provide insights into the role of RAS-dependent pathways in liver cancer differentiation and offer a compelling explanation for the high prevalence of RAS mutations in human CCA compared with HCC. |
High-protein diets alleviate tumour growth and drug resistance by promoting AKT aggregation and turnover. Our results highlight a fine-tuned regulation of AKT by S6K1-mediated phosphorylation and TRAF5-dictated ubiquitination and degradation, offering a strategy for integrating chemotherapy with high-protein diets to enhance cancer treatment efficacy. |
Prevention of rebleeding after primary haemostasis using haemostatic powder in non-variceal upper gastrointestinal bleeding: a multicentre randomised controlled trial. The application of Nexpowder following endoscopic haemostasis significantly reduced both early (3 days) and late (30 days) rebleeding rates in patients with NVUGIB, particularly in cases of ulcer-related bleeding. |
| Hepatology |
Detecting at-risk steatotic liver disease and liver fibrosis in the community. Furthermore, some data suggest community based screening of liver fibrosis in patients with metabolic dysfunction and alcohol-associated SLD is cost-effective. Wide-spread implementation of systematic evidence based diagnostic pathways in the community are needed to reduce the liver related morbidity related to SLD. |
ECM1 protects against liver steatosis through PCBP1-mediated iron homeostasis. Our study reveals that ECM1 is a critical regulator in MASH, modulating lipid peroxidation by maintaining PCBP1-mediated intracellular iron homeostasis. Targeting ECM1 to restore PCBP1-dependent iron homeostasis may offer a novel therapeutic avenue for MASH. |
Galectin-1 modulates glycolysis via a GM1-galactose-dependent pathway to promote hyperthermia resistance in hepatocellular carcinoma. In vivo studies showed that inhibiting Gal-1 in combination with thermal ablation significantly reduced tumor size compared to either monotherapy thermal ablation or Gal-1 inhibition alone. Gal-1 can mediate hyperthermia resistance in HCC and can potentially be modulated as a therapeutic target to reduce rapid progression after thermal ablation. |
Head-to-head comparison of MASH resolution index versus FAST for non-invasive prediction of resolution of MASH on biopsy. The MASH Resolution Index is better than the FAST score in the non-invasive prediction of MASH resolution. These data may have implications for clinical practice and trials. |
Hepatocyte-specific C-C motif chemokine ligand 9 signaling promotes liver fibrosis progression in mice. Ccl9 is a significant contributor to liver fibrosis, influencing macrophage behavior and directly activating HSCs. Targeting Ccl9 offers a potential therapeutic approach for treating liver fibrosis. |
Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trial. Participants who experienced imAEs with STRIDE had a numerical improvement in OS versus those who did not, which was not observed for durvalumab. Long-term OS with STRIDE was observed regardless of imAEs. Most imAEs were low grade, manageable, and occurred in the first 3 months after treatment initiation. Results continue to support the benefits of STRIDE in a diverse population that reflects unresectable HCC globally. |
Management of Immune Tolerant Chronic Hepatitis B. This review highlights the importance of redefining IT CHB to include virological and histological parameters and calls for long-term studies to clarify the role of therapy in reducing fibrosis progression and HCC risk. A more precise understanding of the IT phase is essential to balance the risks of treatment against its potential benefits and to inform future therapeutic strategies. |
Proenkephalin produced by neonatal T-bet+ Treg cells promotes periportal hepatocyte maturation. Our findings uncover a previously unrecognized mechanism through which periportal T-bet+ Treg cells foster liver maturation independently of their immune regulatory functions. It also underscores the critical role of Treg-associated immune zonation in facilitating periportal hepatocyte maturation in neonatal mice. |
Suppressing MASH fibrotic progression by blocking succinate-GPR91 signaling in hepatic stellate cells. HSC-specific GPR91 receptor deficiency effectively halted hepatic fibrosis, probably through two distinct signaling pathways suppressing the succinate-GPR91-Gβγ-ERK/c-jun-smad3 axis that positively regulates HSC activation; and abrogating the GPR91-Gαi-cAMP-NF-κB pathway that hinders their apoptosis. These findings confer GPR91 as a promising target for molecular interventions in blocking MASH-fibrotic progression. |
TATA-box binding protein associated factor 2 (TAF2) in hepatocyte survival and tumorigenesis. TAF2 augmented cancer hallmarks in human HCC cells by binding to the promoters of tumor promoting genes and non-coding RNAs and regulating their transcription. Thus, TAF2 plays a unique and central role in hepatocyte survival and tumorigenesis. |
| J Hepatol |
Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study. Survival benefit and manageable safety continued with durvalumab+GemCis versus placebo+GemCis approximately 3 years after the last participant was randomised. All clinically relevant subgroups were represented in eLTS, supporting standard-of-care status for durvalumab+GemCis in aBTC. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Aliment Pharmacol Ther |
|---|
Review Article: GLP-1 Receptor Agonists and Glucagon/GIP/GLP-1 Receptor Dual or Triple Agonists-Mechanism of Action and Emerging Therapeutic Landscape in MASLD. GLP-1 receptor agonists, alone or in combination with GIP and/or glucagon receptor agonists, represent promising, effective pharmacotherapies for the treatment of MASLD/MASH. Larger and longer-duration clinical trials are needed to further evaluate the efficacy and safety of GIP receptor and glucagon receptor agonism. |
| Clin Gastroenterol Hepatol |
| Gastroenterology |
Pharmacomicrobiomics: The role of the gut microbiome in immunomodulation and cancer therapy. We also shed light on the future perspectives for patients arising from this field. While multiple lines of evidence already demonstrate that the gut microbiome interacts with drugs, and vice versa, thereby affecting treatment efficacy and safety, well-designed clinical studies and integrated in vivo and ex vivo models are necessary to obtain consistent results, improve clinical translation and further unlock the gut microbiome's potential to improve drug responses. |
| Gastrointest Endosc |
| Gut |
| J Hepatol |
misc publications eg case reports, tools of the trade, images of the month, etc…
| Am J Gastroenterol |
|---|
| Clin Gastroenterol Hepatol |
| Endosc Int Open |
| Endoscopy |
| Gastroenterology |
| Gastrointest Endosc |
| Gut |
| Hepatology |
Letters to the editors and authors’ replies
| Aliment Pharmacol Ther |
|---|
| Clin Gastroenterol Hepatol |
| Gastroenterology |
| Gut |
| J Hepatol |